O	0	10	Prevention
O	11	13	of
B-condition	14	18	bone
I-condition	19	23	loss
O	24	28	with
B-intervention	29	40	risedronate
O	41	43	in
O	44	50	breast
O	51	57	cancer
O	58	67	survivors
O	67	68	:
O	69	70	a
O	71	81	randomized
O	81	82	,
O	83	93	controlled
O	94	102	clinical
O	103	108	trial
O	108	109	.

O	110	112	In
O	113	127	postmenopausal
O	128	133	women
O	134	138	with
O	139	142	low
O	143	147	bone
O	148	152	mass
O	153	156	and
O	157	164	hormone
O	164	165	-
O	165	173	receptor
O	173	174	-
O	174	182	positive
O	183	189	breast
O	190	196	cancer
O	197	199	on
O	200	202	an
O	203	212	aromatase
O	213	222	inhibitor
O	222	223	,
O	224	235	risedronate
O	236	246	maintained
O	247	255	skeletal
O	256	262	health
O	263	271	assessed
O	272	274	by
O	275	279	bone
O	280	287	density
O	288	291	and
O	292	300	turnover
O	301	308	markers
O	308	309	.

O	310	315	Women
O	316	320	with
O	321	324	the
O	325	333	greatest
O	334	343	decreases
O	344	346	in
O	347	351	bone
O	352	360	turnover
O	361	368	markers
O	369	371	at
O	372	374	12
O	375	381	months
O	382	385	had
O	386	389	the
O	390	398	greatest
O	399	408	increases
O	409	411	in
O	412	416	bone
O	417	424	density
O	425	427	at
O	428	430	24
O	431	437	months
O	437	438	.

O	439	448	Aromatase
O	449	459	inhibitors
O	460	461	(
O	461	464	AIs
O	464	465	)
O	465	466	,
O	467	475	adjuvant
O	476	485	endocrine
O	486	493	therapy
O	494	497	for
O	498	512	postmenopausal
O	513	518	women
O	519	523	with
O	524	531	hormone
O	531	532	-
O	532	540	receptor
O	540	541	-
O	541	549	positive
O	550	556	breast
O	557	563	cancer
O	563	564	,
O	565	568	are
O	569	579	associated
O	580	584	with
O	585	589	bone
O	590	594	loss
O	595	598	and
O	599	608	fractures
O	608	609	.

O	610	613	Our
O	614	624	objectives
O	625	629	were
O	630	632	to
O	633	642	determine
O	643	645	if
O	646	647	(
O	647	648	1
O	648	649	)
O	650	654	oral
O	655	669	bisphosphonate
O	670	677	therapy
O	678	681	can
O	682	689	prevent
O	690	694	bone
O	695	699	loss
O	700	702	in
O	703	708	women
O	709	711	on
O	712	714	an
O	715	717	AI
O	718	721	and
O	722	723	(
O	723	724	2
O	724	725	)
O	726	731	early
O	732	739	changes
O	740	742	in
O	743	747	bone
O	748	756	turnover
O	757	764	markers
O	765	766	(
O	766	769	BTM
O	769	770	)
O	771	774	can
O	775	782	predict
O	783	788	later
O	789	796	changes
O	797	799	in
O	800	804	bone
O	805	812	mineral
O	813	820	density
O	821	822	(
O	822	825	BMD
O	825	826	)
O	826	827	.

O	828	830	We
O	831	840	conducted
O	841	842	a
O	843	844	2
O	844	845	-
O	845	849	year
O	850	856	double
O	856	857	-
O	857	862	blind
O	862	863	,
O	864	871	placebo
O	871	872	-
O	872	882	controlled
O	882	883	,
O	884	894	randomized
O	895	900	trial
O	901	903	in
B-total-participants	904	907	109
B-eligibility	908	922	postmenopausal
I-eligibility	923	928	women
I-eligibility	929	933	with
I-eligibility	934	937	low
I-eligibility	938	942	bone
I-eligibility	943	947	mass
I-eligibility	948	950	on
I-eligibility	951	953	an
I-eligibility	954	956	AI
I-eligibility	957	958	(
I-eligibility	958	969	anastrozole
I-eligibility	969	970	,
I-eligibility	971	980	letrozole
I-eligibility	980	981	,
I-eligibility	982	984	or
I-eligibility	985	995	exemestane
I-eligibility	995	996	)
I-eligibility	997	1000	for
I-eligibility	1001	1008	hormone
I-eligibility	1008	1009	-
I-eligibility	1009	1017	receptor
I-eligibility	1017	1018	-
I-eligibility	1018	1026	positive
I-eligibility	1027	1033	breast
I-eligibility	1034	1040	cancer
O	1040	1041	.

O	1042	1054	Participants
O	1055	1059	were
O	1060	1070	randomized
O	1071	1073	to
O	1074	1078	once
O	1079	1085	weekly
O	1086	1097	risedronate
O	1098	1100	35
O	1101	1103	mg
O	1104	1106	or
B-control	1107	1114	placebo
O	1114	1115	,
O	1116	1119	and
O	1120	1123	all
O	1124	1132	received
O	1133	1140	calcium
O	1141	1145	plus
O	1146	1153	vitamin
O	1154	1155	D
O	1155	1156	.

O	1157	1160	The
O	1161	1165	main
O	1166	1173	outcome
O	1174	1182	measures
O	1183	1191	included
B-outcome-Measure	1192	1195	BMD
O	1195	1196	,
B-outcome-Measure	1197	1200	BTM
O	1201	1202	[
O	1202	1209	carboxy
O	1209	1210	-
O	1210	1218	terminal
O	1219	1227	collagen
O	1228	1238	crosslinks
O	1239	1240	(
O	1240	1243	CTX
O	1243	1244	)
O	1245	1248	and
O	1249	1250	N
O	1250	1251	-
O	1251	1259	terminal
O	1260	1270	propeptide
O	1271	1273	of
O	1274	1278	type
O	1279	1280	1
O	1281	1292	procollagen
O	1293	1294	(
O	1294	1298	P1NP
O	1298	1299	)
O	1299	1300	]
O	1300	1301	,
O	1302	1305	and
B-outcome-Measure	1306	1312	safety
O	1312	1313	.

O	1314	1320	Eighty
O	1320	1321	-
O	1321	1326	seven
O	1327	1334	percent
O	1335	1344	completed
O	1345	1347	24
O	1348	1354	months
O	1354	1355	.

B-outcome	1356	1359	BMD
O	1360	1369	increased
O	1370	1374	more
O	1375	1377	in
O	1378	1381	the
O	1382	1388	active
O	1389	1398	treatment
O	1399	1404	group
O	1405	1413	compared
O	1414	1416	to
O	1417	1424	placebo
O	1425	1429	with
O	1430	1432	an
O	1433	1441	adjusted
O	1442	1452	difference
O	1453	1455	at
O	1456	1458	24
O	1459	1465	months
O	1466	1468	of
O	1469	1470	3
O	1470	1471	.
O	1471	1472	9
O	1473	1474	±
O	1475	1476	0
O	1476	1477	.
O	1477	1478	7
O	1479	1489	percentage
O	1490	1496	points
B-outcome	1497	1499	at
I-outcome	1500	1503	the
I-outcome	1504	1509	spine
O	1510	1513	and
O	1514	1515	3
O	1515	1516	.
O	1516	1517	2
O	1518	1519	±
O	1520	1521	0
O	1521	1522	.
O	1522	1523	5
O	1524	1534	percentage
O	1535	1541	points
B-outcome	1542	1544	at
I-outcome	1545	1548	the
I-outcome	1549	1552	hip
O	1553	1554	(
O	1554	1558	both
O	1559	1560	p
O	1561	1562	<
O	1563	1564	0
O	1564	1565	.
O	1565	1567	05
O	1567	1568	)
O	1568	1569	.

O	1570	1573	The
O	1574	1582	adjusted
O	1583	1593	difference
O	1594	1601	between
O	1602	1605	the
O	1606	1612	active
O	1613	1622	treatment
O	1623	1626	and
O	1627	1634	placebo
O	1635	1641	groups
O	1642	1646	were
O	1647	1648	0
O	1648	1649	.
O	1649	1651	09
O	1652	1653	±
O	1654	1655	0
O	1655	1656	.
O	1656	1658	04
O	1659	1663	nmol
O	1663	1664	/
O	1664	1668	LBCE
O	1669	1672	for
B-outcome	1673	1676	CTX
O	1677	1680	and
O	1681	1683	23
O	1683	1684	.
O	1684	1685	3
O	1686	1687	±
O	1688	1689	4
O	1689	1690	.
O	1690	1691	8
O	1692	1693	μ
O	1693	1694	g
O	1694	1695	/
O	1695	1697	mL
O	1698	1701	for
B-outcome	1702	1706	P1NP
O	1707	1708	(
O	1708	1712	both
O	1713	1714	p
O	1715	1716	<
O	1717	1718	0
O	1718	1719	.
O	1719	1721	05
O	1721	1722	)
O	1722	1723	.

O	1724	1729	Women
O	1730	1734	with
O	1735	1742	greater
O	1743	1745	12
O	1745	1746	-
O	1746	1751	month
O	1752	1761	decreases
O	1762	1764	in
B-outcome	1765	1768	CTX
I-outcome	1769	1772	and
I-outcome	1773	1777	P1NP
O	1778	1780	in
O	1781	1784	the
O	1785	1791	active
O	1792	1801	treatment
O	1802	1807	group
O	1808	1811	had
O	1812	1813	a
O	1814	1821	greater
O	1822	1824	24
O	1824	1825	-
O	1825	1830	month
O	1831	1839	increase
O	1840	1842	in
O	1843	1849	spinal
O	1850	1853	BMD
O	1854	1855	(
O	1855	1856	p
O	1857	1858	<
O	1859	1860	0
O	1860	1861	.
O	1861	1863	05
O	1863	1864	)
O	1864	1865	.

O	1866	1869	The
O	1870	1874	oral
O	1875	1882	therapy
O	1883	1886	was
B-outcome	1887	1891	safe
I-outcome	1892	1895	and
I-outcome	1896	1900	well
I-outcome	1901	1910	tolerated
O	1910	1911	.

O	1912	1914	In
O	1915	1929	postmenopausal
O	1930	1935	women
O	1936	1940	with
O	1941	1944	low
O	1945	1949	bone
O	1950	1954	mass
O	1955	1958	and
O	1959	1965	breast
O	1966	1972	cancer
O	1973	1975	on
O	1976	1978	an
O	1979	1981	AI
O	1981	1982	,
O	1983	1986	the
O	1987	1991	oral
O	1992	2006	bisphosphonate
O	2007	2018	risedronate
O	2019	2029	maintained
O	2030	2038	skeletal
O	2039	2045	health
O	2045	2046	.
